Investor Presentation Q1 2023
38
Investor presentation
First three months of 2023
The total branded diabetes market has a global value of DKK
~380 billion annually
DKK
billion
Global diabetes market
DKK
The USA
400
+13%
382
billion
+13%
187
■2022
2021
Growth at CER
200
147
+27%
150
314
-17%
98
100
+42%
68
300
-7%
39 41
50
36
15 14
22
0
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
200
+33%
DKK
+12%
Outside the USA
billion
-11%
107 112
142
195
200
168
+45%
97
150
100
-7%
80
-7%
53 54
52
100
+49%
-7%
+47%
68 71
44
38 40
45
50
28
29
0
Total
0
Insulin
GLP-1
DPP-4i
SGLT-2i
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
Source: Company announcements as of Q4 2022
Note: The segment value is based on reported figures, whilst the market growth is under constant exchange rate (CER). For Novo Nordisk the diabetes growth includes Insulin and GLP-1, excluding 'other Diabetes care'.
Novo NordiskⓇView entire presentation